Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study by Vidal Insua, Yolanda et al.
 International Journal of 
Molecular Sciences
Article
Predicting Outcome and Therapy Response in mCRC
Patients Using an Indirect Method for CTCs
Detection by a Multigene Expression Panel:
A Multicentric Prospective Validation Study
Yolanda Vidal Insua 1, Juan De La Cámara 2, Elena Brozos Vázquez 1, Ana Fernández 3,
Francisca Vázquez Rivera 1, Mª José Villanueva Silva 4, Jorge Barbazán 1,
Laura Muinelo-Romay 1,5, Sonia Candamio Folgar 1, Alicia Abalo 1,5, Rafael López-López 1,
Miguel Abal 1 and Lorena Alonso-Alconada 1,*
1 Translational Medical Oncology, Health Research Institute of Santiago de Compostela (IDIS),
University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n,
15706 Santiago de Compostela, Spain; Yolanda.Vidal.Insua@sergas.es (Y.V.I.);
elenambrozosv@hotmail.com (E.B.V.); Francisca.Vazquez.Rivera@sergas.es (F.V.R.);
jorgebarbazan@gmail.com (J.B.); lmuirom@gmail.com (L.M.-R.); soniasigueiro@yahoo.es (S.C.F.);
alicia.abalo.pineiro@sergas.es (A.A.); Rafael.lopez.lopez@sergas.es (R.L.-L.);
miguel.abal.posada@sergas.es (M.A.)
2 Arquitecto Macide Hospital, SERGAS Group, Av. Residencia s/n, 15405 Ferrol, Spain;
juan.cruz.de.la.camara.gomez@sergas.es
3 University Hospital of Ourense, SERGAS Group, Ramon Puga 54, 32005 Ourense, Spain;
afm1003@hotmail.com
4 University Hospital of Vigo, SERGAS Group, Pizarro 22, 36204 Vigo, Spain;
maria.jose.villanueva.silva@sergas.es
5 Liquid Biopsy Analysis Unit, Health Research Institute of Santiago de Compostela (IDIS),
University Hospital of Santiago de Compostela, SERGAS Group, Trav. Choupana s/n,
15706 Santiago de Compostela, Spain
* Correspondence: lorena.alonso.alconada@sergas.es; Tel.: +34-981-955-073
Academic Editor: Peter J. K. Kuppen
Received: 10 March 2017; Accepted: 7 June 2017; Published: 13 June 2017
Abstract: Colorectal cancer (CRC) is one of the major causes of cancer-related deaths. Early detection
of tumor relapse is crucial for determining the most appropriate therapeutic management. In clinical
practice, computed tomography (CT) is routinely used, but small tumor changes are difficult to
visualize, and reliable blood-based prognostic and monitoring biomarkers are urgently needed. The
aim of this study was to prospectively validate a gene expression panel (composed of GAPDH, VIL1,
CLU, TIMP1, TLN1, LOXL3 and ZEB2) for detecting circulating tumor cells (CTCs) as prognostic and
predictive tool in blood samples from 94 metastatic CRC (mCRC) patients. Patients with higher gene
panel expression before treatment had a reduced progression-free survival (PFS) and overall-survival
(OS) rates compared with patients with low expression (p = 0.003 and p≤ 0.001, respectively). Patients
with increased expression of CTCs markers during treatment presented PFS and OS times of 8.95 and
11.74 months, respectively, compared with 14.41 and 24.7 for patients presenting decreased expression
(PFS; p = 0.020; OS; p ≤ 0.001). Patients classified as non-responders by CTCs with treatment, but
classified as responders by CT scan, showed significantly shorter survival times (PFS: 8.53 vs. 11.70;
OS: 10.37 vs. 24.13; months). In conclusion, our CTCs detection panel demonstrated efficacy for
early treatment response assessment in mCRC patients, and with increased reliability compared to
CT scan.
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1. Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide, and it is the third cause
of cancer deaths in western countries [1]. About 25% of cases are diagnosed in an advanced stage and
up to 40% of non-metastatic patients at diagnosis end up developing distant metastasis [2]. Survival in
early stages reaches an 80–95% rate, dropping substantially to ≈8% in metastatic patients. Treatment
of metastatic CRC (mCRC) is generally palliative, with the goal of prolonging overall survival (OS)
and maintaining quality of life. Standard antineoplastic drugs are fluoropyrimidines (fluouracil or
capecitabine), either in monotherapy or combined with oxaliplatin/irinotecan and/or targeted drugs
(anti-vascular endothelial growth factor receptor (anti-VEGFR) like bevacizumab or aflibercept, and
anti-epidermal growth factor receptor (anti-EGFR) like cetuximab or panitumumab, based on Rat
Sarcoma (RAS) oncogene mutation status). These treatments achieve an increase in OS rates from six
to 24 months [3–6]. Nevertheless, and despite advances in the treatment of mCRC, numerous patients
do not respond to therapy and suffer toxicity-related side effects.
Monitoring of patients represents a critical issue in the management of therapeutic strategies.
Currently, the gold standard methodology for evaluating therapy response is computed tomography
(CT). This image-based approach provides reliable information about location and tumor burden,
enabling the clinical community to use of a standardized evaluation for treatment response by response
evaluation criteria in solid tumors (RECIST) [7]. These criteria allow a high specific response, and are
useful when assessing the efficacy of therapeutic agents that operate via a tumor-shrinkage mechanism.
However, different studies suggest that when the way of action of a therapy is mediated by other
mechanisms, such as with immunotherapy or molecular targeted treatments, the tumor size is not
directly correlated with the clinical outcome [8]. Despite undeniable CT utility, occult lesions may be
difficult to visualize with this methodology, which cannot be repeatedly applied as it imposes risks for
the patient, due to repeated ionic radiation and allergenic contrast exposure. In patients with mCRC, a
rapid availability of therapy response data determines the quantity and quality of life, and this still
remains a challenge in oncology, which has not yet progressed with imaging techniques or currently
available molecular markers like carcinoembryonic antigen (CEA).
In the last few years, clinical evidence has indicated a key role for circulating tumor cells (CTCs)
dissemination from primary tumors in the generation of distant metastasis [9]. CTCs detection and
quantification have shown a prognostic value in different tumor types, including CRC, which is why
the CellSearch System (Veridex, Janssen Diagnostics, South Raritan, NJ, USA) was approved by the
American Food and Drug Administration (FDA) for CTCs enumeration in mCRC patients. Using
this system, it has been described that mCRC patients who present three or more CTCs per 7.5 mL
of blood showed poor patient outcome at baseline, e.g., before treatment [10,11]. More interestingly,
CTCs have also been proposed as a treatment response predictive biomarker, mainly in breast cancer.
These findings are being explored in other tumors like prostate, lung or colorectal cancers [12–14].
To date, limited studies have shown the utility of analyzing changes in the number of CTCs or in
their gene expression profiles, during treatment in mCRC patients. In a previous work from our group,
we described the value of CTCs analysis by a multimarker gene expression panel (PrediCTC), which
included intestine-specific and epithelial to mesenchymal transition (EMT) transcripts [15]. CTCs
were immunoisolated from peripheral blood samples before and at four and 16 weeks after treatment
onset, from 50 mCRC patients receiving first-line antineoplastic treatment. Patients with increased
expression of PrediCTC markers along treatment had shorter progression-free survival (PFS) and OS
times, compared to patients where marker expression decreased. Using this multimarker panel, we
could identify patients who were not benefiting from the therapy, earlier than routine CT scans, and
from a minimally invasive liquid biopsy. Of note, PrediCTC identified therapy-refractory patients who
were not detected by standard image techniques, demonstrating improved sensitivity.
The novelty of this new work includes the clinical validation of PrediCTC in a prospective
multicentric study, and the assessment of technology efficacy compared to standard CT scans, with
94 mCRC patients receiving antineoplastic therapy as part of first-line treatments. This allowed
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limitations such as single center and low sample size to be addressed, and to demonstrate PrediCTC
as an efficient therapy response prognostic tool.
2. Results
2.1. Prognostic Value of Circulating Tumor Cells (CTCs) Individual Markers
A total of 94 patients with mCRC were included in this multicentric prospective study for the
validation of PrediCTC as a new technology based on a multimarker gene-panel in circulating tumor
cells (CTCs) for the rapid assessment of therapy response. PrediCTC is based on a combination of
seven CTCs biomarkers previously described by our group, which have demonstrated both diagnostic
and prognostic value in mCRC patients. These markers included TIMP1 and CLU, selected in a
previous global gene expression profiling study developed in our group [16], VIL1 as an epithelial
marker, and LOXL3 and ZEB2 as transcription factors involved in EMT and associated with metastasis
dissemination. We also included TLN1 as a gene involved in CTCs extravasation during metastatic
dissemination [17]. GAPDH was also included as a marker of global cellularity. Finally, PTPRC was
used as an indicator of unspecific cell isolation, and the expression levels of all other genes were
normalized to PTPRC expression levels, as previously reported [18].
The expression levels for each CTCs individual marker are shown in Table S1 as well as the cutoff
value for each biomarker at baseline, and at four- and 16-week time points. As shown in Table 1, all
CTCs-markers that presented an expression above the cutoff (“high CTC” content) showed a direct
correlation with shorter overall survival (OS) rates, both when analyzed at baseline and at four weeks
of treatment. Similarly, patients presenting CTCs gene expression levels (VIL1, CLU, TIMP and LOXL3)
above cut-off at baseline showed a significant reduction in PFS. The same was observed for patients
with GAPDH, LOXL3 and ZEB2 gene expression levels above cut-off at four weeks after treatment
onset (Table 1).
Table 1. Kaplan-Meier survival analysis of progression-free survival (PFS) and overall survival (OS),
according to the expression of individual CTCs markers below (Low) or above (High) the cutoff at
baseline and at four weeks follow-up.
Marker Levels
PFS OS
Mean 95% CI p Value Mean 95% CI p Value
Baseline
GAPDH
Low 14.05 11.83–16.26 0.052 22.93 19.61–26.26 0.041
High 9.40 6.84–11.96 17.30 11.79–22.81
VIL1
Low 14.15 11.94–16.63 0.009 23.60 20.41–26.79 0.001
High 8.69 6.43–10.95 13.90 10.11–17.69
CLU
Low 14.49 12.24–16.75 0.001 23.24 19.92–26.56 0.014
High 7.97 5.93–10.00 16.01 10.96–21.05
TIMP1
Low 14.24 12.09–16.39 0.008 24.32 21.07–27.58 <0.001
High 8.34 5.92–10.77 12.74 8.37–17.11
TLN1
Low 13.66 11.49–15.83 0.210 23.21 20.03–26.39 0.004
High 9.95 7.33–12.56 15.67 10.74–20.61
LOXL3
Low 14.30 11.97–16.63 0.012 23.10 19.78–26.43 0.019
High 8.94 6.77–11.11 16.76 11.45–22.06
ZEB2
Low 14.08 11.78–16.37 0.064 23.53 19.93–27.13 0.009
High 9.39 7.05–11.74 16.32 11.24–21.38
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Marker Levels
PFS OS
Mean 95% CI p Value Mean 95% CI p Value
Four-week follow-up
GAPDH
Low 14.03 11.91–16.15 0.046 24.05 21.02–27.07 <0.001
High 9.01 6.16–11.87 11.85 7.83–15.87
VIL1
Low 13.64 11.48–15.80 0.277 23.06 20.17–25.95 0.006
High 10.31 7.62–13.01 15.165 9.46–20.86
CLU
Low 13.66 11.47–15.84 0.241 22.80 19.90–25.70 0.021
High 10.63 7.69–13.57 16.38 10.45–22.31
TIMP1
Low 13.81 11.65–15.96 0.144 23.89 20.76–27.02 <0.001
High 9.62 6.96–12.28 12.83 9.07–16.59
TLN1
Low 13.66 11.57–15.75 0.268 23.74 20.66–26.82 <0.001
High 9.83 7.00–12.66 13.06 9.10–17.02
LOXL3
Low 14.24 12.05–16.43 0.013 23.75 20.64–26.86 0.001
High 8.53 6.01–11.05 14.31 9.06–19.57
ZEB2
Low 14.02 11.87–16.17 0.049 22.96 19.87–26.06 0.022
High 9.31 6.22–12.39 16.35 10.78–21.91
CI: confidence interval. Data in bold indicates statistically significant p values (p ≤ 0.05).
2.2. PrediCTC Prognostic Value
Taking into account the expression levels of all seven markers together, each patient was assigned
to the “low”- or “high”-CTCs groups, when at least four markers were below or above individual
cut-offs, respectively. From the 94 mCRC patients analysed, 71 (75.53%) relapsed during follow-up, 15
of them (15.96%) being classified as high-CTCs by PrediCTC at baseline and significantly associated
with lower PFS (14.12 vs. 7.73 months; p = 0.003) and shorter OS (23.57 vs. 12.62 months; p≤ 0.001) rates
(Figure 1). Similarly, OS rate was significantly shorter in patients classified as high-CTCs at the four
week time point, after one chemotherapy cycle (23.90 vs. 11.96 months; p≤ 0.001) (Figure 1). Univariate
Cox regression analysis of clinical characteristics showed that the presence of lung metastasis and
the baseline PrediCTC multimarker model were the only two independent prognostic factors for PFS
and OS. Additionally, a significant correlation was found between the four-week follow-up PrediCTC
model and the patients OS rate (Table 2).
These results confirmed the efficacy of the PrediCTC multimarker panel for the evaluation of the
disseminated disease burden, demonstrating a prognostic value, both before treatment onset, and after
one chemotherapy cycle.
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Figure 1. Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) according 
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(C,D). 
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HR (95% CI) HR (95% CI) 
Age (≥66 vs. <66 years) 94 0.76 (0.48–1.22) 0.255 0.99 (0.58–1.69) 0.966 
Sex (female vs. Male) 94 0.69 (0.42–1.14) 0.148 0.45 (0.24–0.87) 0.017
T stage (4 vs. ≤3) 64 0.86 (0.44–1.69) 0.667 0.84 (0.36–1.93) 0.678 
N stage (2 vs. ≤1) 59 1.50 (0.85–2.66) 0.161 0.90 (0.44–1.87) 0.786 
Hepatic mets. (yes vs. no) 91 0.76 (0.36–1.60) 0.474 0.98 (0.42–2.30) 0.964 
Lung mets. (yes vs. no) 91 2.60 (1.54–4.38) <0.001 2.45 (1.39–4.34) 0.002
Peritoneal mets. (yes vs. no) 91 1.27 (0.71–2.30) 0.422 1.53 (0.81–2.92) 0.192 
Ganglionar mets. (yes vs. no) 91 1.26 (0.75–2.12) 0.391 1.00 (0.54–1.85) 0.996 
No. of metastatic sites (≥2 vs. 1) 91 1.41 (0.88–2.26) 0.151 1.40 (0.80–2.44) 0.237 
KRAS (mut. vs. WT) 91 0.92 (0.56–1.52) 0.754 1.07 (0.60–1.91) 0.815 
Baseline CEA (≥10 vs. <10ng/mL) 91 1.27 (0.75–2.14) 0.379 1.03 (0.56–1.89) 0.918 
ECOG PS (2 vs. ≤1) 94 1.51 (0.81–2.82) 0.199 1.91 (0.98–3.74) 0.058 
Figure 1. Kaplan-Meier plots of progression-free survival (PFS) and overall survival (OS) according to
high or low PrediCTC xpressi n levels at baseline (A,B) and four weeks after treatment onset (C,D).
Table 2. Untivariate Cox proportional hazard regression analysis for progression-free survival (PFS)
and overall survival (OS) of patients’ clinical characteristics at baseline and the four-week follow-up
PrediCTC multimarker model.
Covariate n
PFS
p Value
OS
p Value
HR (95% CI) HR (95% CI)
Age (≥66 vs. <66 years) 94 0.76 (0.48–1.22) 0.255 0.99 (0.58–1.69) 0.966
Sex (female vs. Male) 94 0.69 (0.42–1.14) 0.148 0.45 (0.24–0.87) 0.017
T stage (4 vs. ≤3) 64 0.86 (0.44–1.69) 0.667 0.84 (0.36–1.93) 0.678
N stage (2 vs. ≤1) 59 1.50 (0.85–2.66) 0.161 0.90 (0.44–1.87) 0.786
Hepatic mets. (yes vs. no) 91 0.76 (0.36–1.60) 0.474 0.98 (0.42–2.30) 0.964
Lun mets. (yes vs. no) 91 2.60 ( .54–4.38) <0.001 2.45 (1.39–4.34) 0.002
Peritoneal mets. (yes vs. no) 91 1.27 (0.71–2.30) 0.422 1.53 (0.81–2.92) 0.192
Ganglionar mets. (yes vs. no) 91 1.26 (0.75–2.12) 0.391 1.00 (0.54–1.85) 0.996
No. of etastatic sites (≥2 vs. 1) 91 1.41 (0.88–2.26) 0.151 1.40 (0.80–2.44) 0.237
KRAS (mut. vs. WT) 91 0.92 (0.56–1.52) 0.754 1.07 (0.60–1.91) 0.815
Baseline CEA (≥10 vs. <10ng/mL) 91 1.27 (0.75–2.14) 0.379 1.03 (0.56–1.89) 0.918
ECOG PS (2 vs. ≤1) 94 1.51 (0.81–2.82) 0.199 1.91 (0.98–3.74) 0.058
Antibodies therapy (yes vs. no) 94 1.02 (0.64–1.63) 0.932 1.11 (0.65–1.90) 0.711
Baseline CTCs model (high-CTCs vs. low-CTCs) 94 2.33 (1.30–4.15) 0.004 3.37 (1.84–6.18) <0.001
4 weeks CTCs model (high-CTCs vs. low-CTCs) 94 1.71 (0.99–2.95) 0.056 3.30 (1.82–5.99) <0.001
CTCs model (NR vs. R) 92 1.88 (1.09–3.24) 0.022 3.83 (2.10–6.94) <0.001
CTCs: circulating tumor cells; PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence
interval; CEA: carcinoembrionic antigen; ECOG: Eastern Cooperative Oncology Group; PS: performance status;
R: Responder; NR: Non-Responder; mets: metastasis; mut: mutated; WT: wild type. Bold font indicates statistically
significant p-values (p ≤ 0.05).
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2.3. Efficiency of PrediCTC for Clinical Outcome Assessment
After confirming the prognostic value of PrediCTC, we aimed to test its efficiency for the
classification of mCRC patients as responders or non-responders, as well as its predictive potential, by
monitoring CTCs gene expression changes from baseline to the first chemotherapy cycle (four weeks).
Patients were classified as schematized in Figure 2. Patients classified as high-CTCs by PrediCTC
at both baseline and four-week time points, as well as patients presenting an increase in PrediCTC
multimarker levels (e.g., switching from the low-CTCs group at baseline to high-CTCs at four-week
follow-up) were classified as non-responders. Aversely, patients classified as low-CTCs by PrediCTC,
both at baseline and at four-week time points were defined as responders. Finally, patients showing
a decrease in marker expression levels from high-CTCs at baseline to low-CTCs after one cycle of
chemotherapy were initially classified as Responders. However, for those patients, a third sample
(after 16 weeks of treatment) was analyzed to confirm treatment response and to avoid false positives
coming from fast responders with no overtime maintenance. Patients whose treatment response was
not confirmed at the 16-week time point were reclassified as non-responders (see Scheme on Figure 2).
Of note, only seven patients were subjected to a confirmatory sample collection at the 16 week time
point, with only one patient being reclassified as non-responder. This means that 99% of patients
analyzed in this work were classified as responders or non-responders after only one single cycle
of chemotherapy.
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Figure 2. Kaplan-Meier curves showing progression-free survival (PFS) and overall survival (OS) based
on the classification of patients as responders (Resp.) or non-responders (Non-Resp.) according to
changes in circulating tumor cells (CTCs) gene expression levels with the treatment. (A) Classification
of patients at the times of blood sample collection, according to PrediCTC. Kaplan-Meier curves for (B)
PFS and (C) OS.
Kaplan-Meier survival analysis showed that the mean PFS rate was 8.95 months for patients
classified as non-responders (n = 22; 23.40%), significantly lower compared to the mean 14.41 months
PFS for patients classified as responders (n = 70; 74.47%) (p = 0.020; Figure 2). In line with these findings,
the mean OS rate was significantly reduced in patients classified as non-responders (11.74 months)
compared to those classified as Responders (24.7 months) (p ≤ 0.001; Figure 2). Hazard ratios (HR) for
the non-responder group (univariate Cox regression) was 1.88 for PFS (95% CI: 1.09–3.24, p=0.022) and
3.83 for OS (95% CI: 2.10–6.94, p < 0.001; Table 2). All variables that showed a significant prognostic
value in the univariate analysis were independent predictors of worse PFS and OS in a multivariate
analysis (Table 3).
Table 3. Multivariate Cox regression analysis for progression-free survival (PFS) and overall
survival (OS) of patients’ clinical characteristics at baseline, and the four-week follow-up PrediCTC
multimarker model.
Covariates n
PFS
p Value χ2 (1)
OS
p Value χ2 (1)
HR (95% CI) HR (95% CI)
Lung metastasis
(yes vs. no) 91
2.82
(1.66–4.78) <0. 01 18.63
2.75
(1.54–4.90) 0.001 22.29
Baseline CTCs model
(high-CTCs vs. low-CTCs)
2.42
(1.33–4.43) 0.0 4
3.66
(1.93–6.92) <0.0 1
Lung metastasis
(yes vs. no) 91
2.81
(1.65–4.77) <0. 01 15.31
2.49
(1.41–4.15) 0.002 20.85
4 weeks CTCs model
(high-CTCs vs. low-CTCs)
1.80
(1.02–3.19) 0.043
3.22
(1.74–5.95) <0.0 1
Lung metastasis
(yes vs. no) 89
3.09
(1.80–5.30) <0. 01 18.50
2.76
(1.54–4.95) 0.001 25.80
CTCs model
(NR vs. R)
2.06
(1.17–3.62) 0.012
3.82
(2.06–7.09) <0.001
CTCs: circulating tumor cells; PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence
interval; R: Responder; NR: Non-Responder. Data in bold indicates statistical significance (p ≤ 0.05). (1) Significance
of a χ-square test for multivariate models.
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These data confirmed our previous results obtained with a multimarker gene panel and validated
PrediCTC as a predictive tool for the monitoring of therapy response in mCRC patients. Importantly,
PrediCTC demonstrated efficacy after only one cycle of chemotherapy, earlier than routine imaging
techniques (CT scan).
2.4. Competitive Advantage of PrediCTC versus Standard Computed Tomography (CT) Scan Monitoring
In addition to efficiently assessing therapy response earlier than current standard monitoring
techniques, we also evaluated the competitive advantage of PrediCTC to more reliably identify patients
responding or not responding to therapy. As shown in Figure 3, 68 patients included in the study
(72.34%) were equally classified by PrediCTC and CT scan, 66 patients (70.21%) as responders and
2 patients (2.13%) as non-responders. Mean PFS and OS rates for patients classified as responders
by both techniques were significantly higher (PFS: 14.94, 95% CI: 12.68–17.19; OS: 24.63, 95% CI:
21.55–27.71) compared to those classified as non-responders (PFS: 1.45, 95% CI: 0.50–2.40; OS: 6.22
95% CI: 1.02–11.41) Interestingly, 17 patients (18.08%) were classified as non-responders by PrediCTC
while they were defined as responders by CT scan. These patients evidenced a significantly reduced
PFS and OS, compared with those defined as Responders by CT scan, demonstrating the improved
ability of PrediCTC to identify those patients that are likely not responding to therapy (Figure 3). In
addition, PrediCTC was also able to correctly classify one patient responding to therapy and identified
as a non-responder by CT scan (Figure 3).
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Overall, PrediCTC demonstrated an improved sensitivity for identification of therapy responders,
after only one cycle of chemotherapy (four weeks), compared to a CT scan performed at the third cycle
of therapy (12 weeks) (60% for PrediCTC versus 17.4% by CT scan). The specificity of the CT scan was
98.5%, compared to 89.6% with PrediCTC. This resulted in a PrediCTC Positive Predictive Value of
68.2%, defined as the probability of correctly classifying non-responders, and a negative predictive
value of 85.7%, defined as the probability of correctly classifying responders. Consequently, PrediCTC
drastically reduced the false negative rate from 82.6% as shown by CT scan, to 40%, meaning that
PrediCTC is more efficient than CT scan at correctly identifying those patients that are not responding
to therapy. In conclusion, PrediCTC demonstrated an improved global efficiency, defined as the
probability of correctly classifying responders and non-responders among the whole population of
false and real positive and negative patients, being 81.5% by PrediCTC versus 77.3% for the CT scan,
in this multicentric study.
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3. Discussion
Although the utility of CTCs in identifying patients with early stage disease who are at risk
of developing recurrence, or as a tool to assess tumor therapy response is evident, the reality is
that among all the approaches that have been developed for CTCs isolation and characterization,
only the CellSearch System has been cleared by the FDA for its clinical use [19]. Using this system,
the prognostic utility of CTCs detection has been recently evaluated in a meta-analysis composed
of eleven studies, including 1847 patients with CRC [20]. The incidence of CTCs was significantly
higher in the metastasis-positive group compared to the metastasis-negative group, as well as in the
hepatic-metastasis-positive group. The presence of CTCs was significantly related to OS (HR = 2.00,
95% CI (1.49, 2.69), p < 0.01) and PFS (HR = 1.80, 95% CI (1.52, 2.13), p < 0.01), and for the CTCs positive
group, the response rate both at baseline and during treatment, was significantly lower than for the
negative group.
Despite its utility, the implementation of CTCs detection into the clinical practice remains a
pending matter, and there exists a clear necessity to improve CTCs detection rate in mCRC disease with
alternative or complementary technologies, to translate the use of CTCs as on-treatment biomarkers in
future studies. For example, the analysis of CTCs, alone or in combination with CEA, may be a useful
tool in monitoring the response to treatment in mCRC [21]. Also, the quantification of CTCs combining
two methodologies, CellSearch and AdnaTest, demonstrated an improved detection of CTCs in a
47 mCRC patient cohort [22]. The requirement for improved sensitivity in CTCs detection has also
been identified for the management of patients undergoing surgery [23]. We must also consider that
the CTCs cohort in mCRC patients may be composed not only of epithelial tumor cells, but also tumor
cells that have undergone transformation due to the epithelial-mesenchymal transition, and tumor
stem cells [24]. Regarding to this fact, recent studies have demonstrated that, at the time of surgery,
the detection of CTCs with CK20 by real-time polymerase chain reaction (RT-PCR) without using
anti-EpCAM immunoisolation, is an independent prognostic factor for OS and DFS in colon cancer
patients [25]. Likewise, the use of a complementary noninvasive tool in liquid biopsy, circulating
tumor DNA (ctDNA), allows early diagnosis, prognosis and follow-up of response and resistance to
therapy. In fact, the analysis of ctDNA in colorectal cancer patients may be a valuable biomarker that
negatively correlates with survival [26]. Nevertheless, both CTCs and ctDNA-based liquid biopsies
are promising tools for monitoring tumor dynamics, and should be standardized and validated in
different independent trials, in order to be incorporated into standard clinical practice [27].
In this work, we presented a prospective multicentric study conducted in four hospitals of the
public Galician health system, to validate the use of the PrediCTC marker panel in the prediction of
outcome and therapy response in 94 mCRC patients. As shown, and in addition to its prognostic
value, PrediCTC efficiently identified those patients that do not respond to first-line chemotherapy
and presented reduced PFS and OS rates, after only one cycle of treatment. Moreover, for patient
monitoring, PrediCTC relied only on a minimally invasive blood test, compared to sophisticated and
complex standard CT scans. Finally, after only one chemotherapy cycle, PrediCTC demonstrated an
improved efficiency in the evaluation of responses compared to CT scan imaging, which is performed
at the third cycle of treatment (e.g., two months later than PrediCTC). This represents not only the
elimination of two cycles of inefficacious therapy regimes that may cause undesirable secondary effects,
but also reduces periods of uncertainty for patients and the oncologists regarding the assessment of
response. In addition, to allow a rapid clinical decision when a therapy is not resultantly effective,
PrediCTC might represent a saving in resources to the public health system. We are currently evaluating
the cost-effectiveness of PrediCTC for its implantation in clinical routines.
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4. Materials and Methods
4.1. Patients
A total of 94 mCRC patients, without prior treatment for metastatic disease were recruited at four
hospitals in Spain (University Clinical Hospital of Santiago de Compostela, University Clinical Hospital
of Ferrol, University Clinical Hospital of Ourense and University Clinical Hospital of Vigo). All patients
signed an informed consent approved by the relevant ethical committee (RLL-ANT-2014-01; 17 October
2014; Rede Galega de Comités de Ética da Investigación). Inclusion criteria were: age ≥18 years,
measurable mCRC (Stage IV), performance status of 0–2 based on the Eastern Cooperative Oncology
Group (ECOG) scores, and the initiation of chemotherapy as first-line treatment. Patients with previous
cancer diagnoses were not included in the study. Patient characteristics are summarized in Table 4.
Metastasis location and the evolution of the disease were analyzed by a radiologist, using standard
imaging techniques (CT scan) and following RECIST 1.1 guidelines [7]. Progressive disease was
defined when there was at least a 20% increase in the sum of diameters of target lesions and/or the
appearance of one or more new lesions. Patients dying from the disease during the follow-up period
without being evaluated by CT scan were also considered as progression of disease. A volume of
7.5 mL of peripheral blood was collected from all patients at three different time points: just before
initiation of treatment (baseline), after the first cycle of chemotherapy (four weeks) and before Cycle 5
(16 weeks).
Table 4. Patient characteristics.
Characteristic n (%) Characteristic n (%)
Gender Metastasis location
Male 59 (62.77) Liver 38 (40.43)
Female 35 (37.23) Liver and other 44 (46.81)
Primary tumor location Nonliver 9 (9.57)
Colon 63 (67.02) Unknown 3 (3.19)
Rectum 29 (30.85) ECOG PS grade
Both 2 (2.13) 0 10 (10.64)
KRAS status 1 70 (74.47)
Wild type 55 (58.51) 2 14 (14.89)
Mutated 36 (38.30) First-line chemotherapy
Unknown 3 (3.19) Folfox 70 (74.47)
T Folfiri 11 (11.70)
T1–T2 3 (3.19) Capecitabine 5 (5.32)
T3 46 (48.94) Capecitabine-Oxaliplatin 6 (6.38)
T4 15 (15.96) Irinotecan 2 (2.13)
Tx 30 (31.91) First-line combined biological therapy
N Anti-EGFR 35 (37.23)
N0 10 (10.63) Anti-VEGF 12 (12.76)
N1 24 (25.53) None 47 (50)
N2 25 (26.59)
N3 1 (1.06)
Nx 34 (36.17)
Number of metastatic
sites
1 45 (47.88)
≥2 46 (48.93)
Unknown 3 (3.19)
ECOG: Eastern Cooperative Oncology Group; PS: performance status; N: Nodal involvement; N0: no regional
lymph nodes containing cancer cells; N1: metastasis in 1 to 3 lymph nodes; N2: metastasis into 4 or more lymph
nodes; N3: metastasis into any nodes along the course of named vascular trunks; Nx: unknown; EGFR: epidermal
growth factor receptor; VEGF: vascular endothelial growth factor.
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4.2. CTCs Immunoisolation and Gene Expression Analysis
CTCs were isolated using CELLection Epithelial Enrich Dynabeads (Invitrogen, Dynal, Oslo,
Norway) coated with monoclonal antibodies against human epithelial cell adhesion molecules
(EpCAM), according to the user’s guide. RNA extraction and RT-qPCR were carried out as previously
described [16]. mRNA isolation from CTCs samples was performed using the QiampViral kit (Qiagen,
Valencia, CA, USA), optimized for very low cellularity samples, following manufacturer’s instructions.
cDNA was synthesized using SuperScript III (Invitrogen, Carlsbad, CA, USA) and genes were
specifically pre-amplified using the TaqMan®PreAmp Master Mix kit (Applied Biosystems, Foster City,
CA, USA). Quality tests, data mining, and interpretation were performed as described [15,16,18].
mRNA levels of a panel of six genes (GAPDH, VIL1, CLU, TIMP1, LOXL3 and ZEB2), previously
identified in a global gene expression analysis of immunoisolated CTCs from mCRC patients [18], with
the inclusion of the TLN1 gene [16], were quantified in a StepOne plus thermocycler (Life Technologies,
Carlsbad, CA, USA). TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) for
selected genes (Table S2) were used, and sensitivity was demonstrated (Figure S1). As the analyzed
genes are not exclusively expressed in CTCs but also in contaminating leucocytes, the expression levels
of PTPRC (or CD45) were assessed to normalize marker expression levels against the background
of unspecific immune-isolation; no differences were found for CD45 expression during treatment
(Figure S2). We already described the utility of PTPRC as a reference gene [16], as its expression
levels are equal in mCRC patient samples and in healthy donors. All genes and appropriate positive
and negative controls were measured in duplicate. Cq values (defined as the cycle number at which
the fluorescence of a sample crosses a fixed threshold line) for each transcript were normalized to
40 (maximum number of cycles), and this value was then normalized to the 40-Cq value for PTPRC
((40-Cq target)-(40-Cq), to simplify interpretation of results. Accuracy of the methodology in terms of
recovery rate (>90%), as well as non-interference of contaminating leukocytes, have been previously
described [16].
4.3. Data evaluation and Statistical Analysis
Computed tomography was performed every 12 weeks from treatment onset. According
to RECIST criteria, patients with stable disease, partial or complete response were classified as
therapy responders, whereas patients with progressive disease were defined as non-responders.
Progression-free survival (PFS) and overall survival (OS) rates were defined as the time (in months)
between the first treatment day until disease progression or death, respectively.
Based on CTCs gene expression markers, patient with expression levels below or above the cutoff
for 4 of the analyzed genes was included into low or high-CTCs groups, respectively. The cutoff value
of each gene was determined according to a prior study [15] and established as the 75% percentile for
each individual marker.
4.4. Statistical Analysis
To determine the association between progression-free survival or overall survival and gene
markers levels, a Kaplan-Meier with log-rank test and univariate and multivariate COX regression
survival analyses were used. A p value < 0.05 was considered statistically significant. Analyses were
performed using SPSS 19.0 (SPSS Inc., Chicago, IL, USA).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/6/1265/s1.
Acknowledgments: We gratefully thank all the patients for their willingness to participate in the study and the
staff of the medical oncology department for their collaboration in sample collection. Program for pre-commercial
development of research results of the Galician Public Health System; ACIS (Axencia de Coñecemento en Saude);
SERGAS. Cofinanced ERDF Funds 2007–2013.
Int. J. Mol. Sci. 2017, 18, 1265 12 of 14
Author Contributions: Jorge Barbazán and Miguel Abal conceived and designed the experiments;
Lorena Alonso-Alconada performed the experiments; Yolanda Vidal Insua, Laura Muinelo Romay and
Lorena Alonso-Alconada analyzed the data; Yolanda Vidal Insua, Juan de la Cámara, Elena Brozos
Vázquez, Mª José Villanueva Silva, Ana Fernández, Francisca Vázquez Rivera, Sonia Candamio Folgar and
Rafael López-López contributed to the patients inclusion and follow-up, Alicia Abalo contributed to the sample
management, Yolanda Vidal Insua, Miguel Abal and Lorena Alonso-Alconada wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish the results.
Abbreviations
CRC Colorectal cancer
mCRC Metastatic colorectal cancer
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